| Aug 19 |
ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious
|
| Aug 12 |
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
|
| Jul 31 |
Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop
|
| Jun 25 |
ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
|
| Jun 23 |
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
|
| Jun 20 |
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
| Jun 20 |
ImmunityBio spikes after commercial update on lead drug Anktiva
|
| Jun 20 |
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
|
| Jun 7 |
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
|
| Jun 6 |
ImmunityBio: Anktiva's Launch Demands A Reassessment
|
